A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants
- Registration Number
- NCT03943056
- Lead Sponsor
- Biogen
- Brief Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of BIIB091 in healthy participants.This study will also determine the effect of food on the single oral dose pharmacokinetic (PK).
- Detailed Description
Initial protocol recruitment and follow up was completed by 10 Jan 2020 with an optional cohort intended for completion by April 2020. Subsequently, a decision was made not to progress this optional cohort in light of COVID-19 which has resulted in a delay in reporting the actual completion date.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with applicable participant privacy regulations.
- Have a body mass index between 18 and 30 kg/m2, inclusive.
- All male participants must practice highly effective methods of contraception and not donate sperm during the study and for at least 1 spermatogenic cycle (90 days) after administration of last dose of study treatment.
- All female participants of childbearing potential must practice highly effective methods of contraception and not donate eggs during the study and for at least 90 days after their last dose of study treatment.
- Must be in good health as by the Investigator, based on medical history and screening evaluations.
Key
Exclusion Criteria
- History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic,hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
- History of severe allergic or anaphylactic reactions, or of any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment.
- History of, or ongoing, malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to Check-in).
- Current enrollment or plan to enroll in any other drug, biological, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days prior to Check-in, or 5 half-lives of the drug or therapy, whichever is longer.
- Breastfeeding, pregnant, or planning to become pregnant during study participation.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description (SAD): Cohort 2A BIIB091 Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1. Single Ascending Dose (SAD): Cohort 1A BIIB091 Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1. Single Ascending Dose (SAD): Cohort 1A Placebo Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1. (SAD): Cohort 2A Placebo Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1. (SAD): Cohort 3A BIIB091 Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal. (SAD): Cohort 3A Placebo Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal. (SAD): Cohort 4A BIIB091 Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1. (SAD): Cohort 4A Placebo Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1. (SAD): Cohort 5A BIIB091 Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1. (SAD): Cohort 5A Placebo Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1. Multiple Ascending Dose (MAD): Cohort 1B BIIB091 Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14. Multiple Ascending Dose (MAD): Cohort 1B Placebo Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14. (MAD): Cohort 2B BIIB091 Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14. (MAD): Cohort 2B Placebo Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14. (MAD): Cohort 3B Placebo Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14. (MAD): Cohort 3B BIIB091 Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
- Primary Outcome Measures
Name Time Method Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Baseline up to Day 9 for SAD Cohorts; Baseline up to Day 24 for MAD Cohorts An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death, in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event), however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.
- Secondary Outcome Measures
Name Time Method Area Under the Curve from Time 0 to the Time of the Last Measurable Concentration (AUClast) Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) Baseline and multiple timepoints up to Day 3 Maximum Observed Concentration (Cmax) Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 14 for MAD Cohorts Time to Reach Maximum Observed Concentration (Tmax) Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 14 for MAD Cohorts Elimination Half-Life (t½) Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts Apparent Total Body Clearance (CL/F) Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) Baseline and multiple timepoints up to Day 3 for SAD Cohorts; Baseline and multiple timepoints up to Day 16 for MAD Cohorts Amount of BIIB091 Excreted in Urine per Sampling Interval (Aeu) Baseline and multiple timepoints up to Day 3 Percentage of BIIB091 Excreted in Urine per Sampling Interval (%Feu) Baseline and multiple timepoints up to Day 3 Renal clearance (CLr) Baseline and multiple timepoints up to Day 3 Accumulation Ratio (R) Baseline and multiple timepoints up to Day 16 Trough concentration (Ctrough) Baseline and multiple timepoints up to Day 16 Area Under the Concentration-Time Curve Within a Dosing Interval (AUCtau) Baseline and multiple timepoints up to Day 16
Trial Locations
- Locations (1)
Research Site
🇺🇸Dallas, Texas, United States